NLRP3 and Hypoglycemia: MCC950 is a sulfonylurea derivative and a selective inhibitor of NLRP3, specifically inhibiting the activation of NLRP3 without affecting AIM2, NLRC4, or NLRP1 inflammasomes, with no risk of hypoglycemia (123, 130).